financetom
Business
financetom
/
Business
/
KP Tissue Q1 Net Income, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
KP Tissue Q1 Net Income, Revenue Rise
May 26, 2025 7:38 AM

08:13 AM EDT, 05/14/2025 (MT Newswires) -- KP Tissue ( KPTSF ) on Wednesday said first-quarter net income and revenue rose.

Net income for Kruger products increased to $15.4 million from $9 million in the prior year period. The company did not provide per share amounts. The increased profit was primarily due to a bigger foreign exchange gain and higher adjusted EBITDA.

Kruger products revenue jumped 14% to $546.1 million, beating the FactSet consensus analyst forecast of $518.2 million. The increase was primarily due to higher sales volume in the Consumer segment and favorable selling prices across both segments and higher forex gains.

"We are pleased with our strong first-quarter results, especially considering the uncertain and volatile economic environment," said KP Tissue ( KPTSF ) Chief Executive Dino Bianco. "Adjusted EBITDA reached $75.8 million in the quarter on revenue that increased nearly 14% year-over-year. Revenue for the Consumer segment was driven by higher sales volume in Canada and in the U.S., and improved pricing."

Bianco added that the impact of tariffs on Kruger Products during the quarter was "not significant."

KP Tissue ( KPTSF ) will pay a quarterly dividend of $0.18 per share on July 15.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Eli Lilly posts strong Q1 results, but weight-loss drug sales disappoint
Eli Lilly posts strong Q1 results, but weight-loss drug sales disappoint
May 25, 2025
(Reuters) - Eli Lilly ( LLY ) on Thursday posted better-than-expected first quarter revenue and profit, although sales of its popular weight-loss drug, Zepbound, came in slightly below Wall Street estimates, sending its shares down 2% in premarket trading. The success of the company's diabetes and weight loss treatments has led Eli Lilly ( LLY ) to become the world's...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Biogen beats quarterly profit estimates on strong demand for rare disease drugs
Biogen beats quarterly profit estimates on strong demand for rare disease drugs
May 25, 2025
(Reuters) -Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis drugs. The drugmaker has been counting on newer launches such as genetic disorder drug Skyclarys as demand falls for its once top-selling multiple sclerosis medicines in the face of stiff competition in a crowded...
Harley-Davidson pulls annual forecasts over tariff concerns
Harley-Davidson pulls annual forecasts over tariff concerns
May 25, 2025
May 1 (Reuters) - Harley-Davidson ( HOG ) on Thursday suspended its annual forecasts as the motorbike maker navigates headwinds related to U.S. President Donald Trump's tariffs. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved